Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Roche (RHHBY) is a drug manufacturers - general company based in Basel, Switzerland. In Q4 2025, it reported revenue of $34.26B.
RocheSwiss diversified pharma. Carmot acquisition (December 2023, $2.7B) brought CT-388 (about 23% placebo-adjusted weight loss at 48 weeks Phase 2), CT-996 oral, and CT-868. Zealand licensing deal ($1.65B) added petrelinitide amylin program.
H1 2006-H2 2025
H1 2016-H2 2025
H1 2016-H2 2025
Roche (RHHBY) is a Drug Manufacturers - General company. Swiss diversified pharma. Carmot acquisition (December 2023, $2.7B) brought CT-388 (about 23% placebo-adjusted weight loss at 48 weeks Phase 2), CT-996 oral, and CT-868. Zealand licensing deal ($1.65B) added petrelinitide amylin program. It was founded in 1896, is headquartered in Basel, Switzerland and employs about 103,249 people.
Track Roche's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated July 24, 2026.
Sterling groups Roche in the GLP-1 sector, alongside Pfizer (PFE), Amgen (AMGN) and AstraZeneca (AZN).
If you are researching Roche, also look at Pfizer (PFE), Amgen (AMGN) and AstraZeneca (AZN). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.